Stock Track | Fulgent Genetics Soars 19.81% on Strong Q3 Results and Raised 2025 Outlook

Stock Track2025-11-07

Shares of Fulgent Genetics Inc. (FLGT) are skyrocketing 19.81% in pre-market trading on Friday following the company's impressive third-quarter results and increased full-year guidance. The genetic testing and therapeutics company demonstrated strong performance, beating analyst expectations and showing promising growth in key areas.

Fulgent reported Q3 revenue of $84.07 million, surpassing the analyst consensus estimate of $81.43 million and representing a 17.2% year-over-year increase. The company's adjusted earnings per share came in at $0.14, significantly beating the estimated loss of $0.22 per share. This strong financial performance was driven by robust momentum in Fulgent's laboratory services business and progress in clinical trials, particularly for its FID-007 program.

In light of these positive results, Fulgent has raised its full-year 2025 revenue guidance to $325 million from the previous $320 million, reflecting management's confidence in the company's strategic execution. CEO Ming Hsieh highlighted the progress in therapeutic development as a key contributor to the quarter's success. Additionally, the company expects to have $800 million in cash and investments by year-end, further strengthening its financial position. The market's enthusiastic response to this news underscores investor optimism about Fulgent's growth trajectory and its positioning in the genetic testing and therapeutics space.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195252105?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195252105","market":"nz","top_or_hot":-1,"title":"Stock Track | Fulgent Genetics Soars 19.81% on Strong Q3 Results and Raised 2025 Outlook","media":"Stock Track","content":"<p>Shares of Fulgent Genetics Inc. (FLGT) are skyrocketing 19.81% in pre-market trading on Friday following the company's impressive third-quarter results and increased full-year guidance. The genetic testing and therapeutics company demonstrated strong performance, beating analyst expectations and showing promising growth in key areas.</p>\n\n<p>Fulgent reported Q3 revenue of $84.07 million, surpassing the analyst consensus estimate of $81.43 million and representing a 17.2% year-over-year increase. The company's adjusted earnings per share came in at $0.14, significantly beating the estimated loss of $0.22 per share. This strong financial performance was driven by robust momentum in Fulgent's laboratory services business and progress in clinical trials, particularly for its FID-007 program.</p>\n\n<p>In light of these positive results, Fulgent has raised its full-year 2025 revenue guidance to $325 million from the previous $320 million, reflecting management's confidence in the company's strategic execution. CEO Ming Hsieh highlighted the progress in therapeutic development as a key contributor to the quarter's success. Additionally, the company expects to have $800 million in cash and investments by year-end, further strengthening its financial position. The market's enthusiastic response to this news underscores investor optimism about Fulgent's growth trajectory and its positioning in the genetic testing and therapeutics space.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Fulgent Genetics Soars 19.81% on Strong Q3 Results and Raised 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Fulgent Genetics Soars 19.81% on Strong Q3 Results and Raised 2025 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 22:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Fulgent Genetics Inc. (FLGT) are skyrocketing 19.81% in pre-market trading on Friday following the company's impressive third-quarter results and increased full-year guidance. The genetic testing and therapeutics company demonstrated strong performance, beating analyst expectations and showing promising growth in key areas.</p>\n\n<p>Fulgent reported Q3 revenue of $84.07 million, surpassing the analyst consensus estimate of $81.43 million and representing a 17.2% year-over-year increase. The company's adjusted earnings per share came in at $0.14, significantly beating the estimated loss of $0.22 per share. This strong financial performance was driven by robust momentum in Fulgent's laboratory services business and progress in clinical trials, particularly for its FID-007 program.</p>\n\n<p>In light of these positive results, Fulgent has raised its full-year 2025 revenue guidance to $325 million from the previous $320 million, reflecting management's confidence in the company's strategic execution. CEO Ming Hsieh highlighted the progress in therapeutic development as a key contributor to the quarter's success. Additionally, the company expects to have $800 million in cash and investments by year-end, further strengthening its financial position. The market's enthusiastic response to this news underscores investor optimism about Fulgent's growth trajectory and its positioning in the genetic testing and therapeutics space.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FLGT","symbol_name":"Fulgent Genetics Inc.","start_time":0,"source_url":"","article_id":"1195252105","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195252105","pubTimestamp":1762526908,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Fulgent Genetics Inc. (FLGT) are skyrocketing 19.81% in pre-market trading on Friday following the company's impressive third-quarter results and increased full-year guidance. The genetic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FLGT":"Fulgent Genetics Inc."},"translate_title":"个股赛道|Fulgent Genetics第三季度业绩强劲飙升19.81%并上调2025年展望","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FLGT":1},"content_text":"Shares of Fulgent Genetics Inc. (FLGT) are skyrocketing 19.81% in pre-market trading on Friday following the company's impressive third-quarter results and increased full-year guidance. The genetic testing and therapeutics company demonstrated strong performance, beating analyst expectations and showing promising growth in key areas.\nFulgent reported Q3 revenue of $84.07 million, surpassing the analyst consensus estimate of $81.43 million and representing a 17.2% year-over-year increase. The company's adjusted earnings per share came in at $0.14, significantly beating the estimated loss of $0.22 per share. This strong financial performance was driven by robust momentum in Fulgent's laboratory services business and progress in clinical trials, particularly for its FID-007 program.\nIn light of these positive results, Fulgent has raised its full-year 2025 revenue guidance to $325 million from the previous $320 million, reflecting management's confidence in the company's strategic execution. CEO Ming Hsieh highlighted the progress in therapeutic development as a key contributor to the quarter's success. Additionally, the company expects to have $800 million in cash and investments by year-end, further strengthening its financial position. The market's enthusiastic response to this news underscores investor optimism about Fulgent's growth trajectory and its positioning in the genetic testing and therapeutics space.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195252105","isCrawlerRequest":true}